- Company launches first Zerenia™ medical cannabis clinic outside
of Colombia, exporting proven
clinic model via strategic partnership with Lima-based Clinica Montesur
- Clinica Montesur is a specialized medical clinic with over 90
doctors covering 19 specialties and 11,000 patient transactions
annually; its clinic is centrally located in Lima, Peru, a city of 10 million people or a
third of the country's total population
- Partnership combines Khiron's unique medical cannabis
expertise, including the Company's real-world evidence, medical
education, best practices and systems, with Clinica Montesur's
patient base, clinical infrastructure and medical staff
- In Q1 2021, Khiron's medical cannabis sales in Peru increased by over 175% compared to total
sales in 2020
- Zerenia™ is the category leader in medical cannabis sales in
Colombia, with over 20,000 filled
prescriptions and over 8,000 individual patients to date, 50%
patient retention, and average 90% gross margins
- The new Zerenia location brings Khiron's total clinic count to
11 across Latin America
TORONTO, June 10, 2021 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF)
(Frankfurt: A2JMZC), a vertically
integrated cannabis leader with core operations in Latin America and Europe, today announces the launch of its
first ZereniaTM clinic outside of Colombia, in Lima,
Peru. Following the success of the Company's clinic strategy
in Colombia, the new clinic has
been established as a strategic partnership between Khiron and
Clinica Montesur, a specialized medical provider in Lima with over 90 physicians and more than
11,000 patient transactions annually.
Khiron launches first Zerenia medical cannabis clinic, via a
strategic partnership with Lima-based Clinica Montesur
Alvaro Torres, CEO and Director
comments, "I am pleased to announce the first expansion of our
Zerenia brand beyond Colombia.
Knowing that prescription rates at our Zerenia clinics are 14 times
higher than those of our external clinic partners, we are excited
to bring a proven marketing, sales, and distribution model to a
market of over ten million people. To date, our Zerenia clinics
have played a vital role in not only introducing patients to Khiron
products, but also in developing an exceptional patient experience
and growing base of returning patients. As we continue to develop
our unique, service-oriented platform, we are proud to introduce
Zerenia to the Peruvian market, where initial reception to
our products has been strong since sales began late last year."
With over 30 years of experience in Peru, Clinica Montesur is dedicated to high
quality care across 19 areas of specialization, including oncology,
dermatology, ophthalmology, and psychology. As part of the
strategic partnership, Clinica Montesur will provide clinic
infrastructure, including its medical facility, clinic permits,
systems, and medical staff, among others. The partnership will
leverage Khiron's unique ZereniaTM medical cannabis
model, including the Company's medical cannabis education platform,
real-world evidence, and standard operating procedures. Patients of
the clinic will be able to fill prescriptions for High THC and Low
THC (CBD) medical cannabis at ten Farmacia Universal S.A.C.
locations throughout Lima, as
previously announced by the Company.
About Khiron Life Sciences Corp.
Khiron is a leading
vertically integrated medical cannabis company with core operations
in Latin America and Europe. Leveraging wholly-owned medical health
centres and proprietary telemedicine platforms, Khiron combines a
patient-oriented approach, physician education programs, scientific
expertise, product innovation, and agricultural infrastructure to
drive prescriptions and brand loyalty with patients worldwide. The
Company has a sales presence in Colombia, Peru, Germany
and the UK, and is positioned to commence sales in Mexico and Brazil in 2021. The Company is led by
Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and
diverse executive team and Board of Directors.
Visit Khiron online at investors.khiron.ca and on Instagram
@khironlife.
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment on
analyses, expectations or statements made by third-parties in
respect of Khiron, its securities, or financial or operating
results (as applicable). Although Khiron believes that the
expectations reflected in forward-looking statements in this press
release are reasonable, such forward-looking statement has been
based on expectations, factors and assumptions concerning future
events which may prove to be inaccurate and are subject to numerous
risks and uncertainties, certain of which are beyond Khiron's
control, including the risk factors discussed in Khiron's Annual
Information Form which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and is made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
SOURCE Khiron Life Sciences Corp.